Welcome to HitGen

News

Get up to date with the latest HitGen articles and join us in the events

  1. News
  2. Press Release

Press Release

  • 23 December 2021
    Lipigon and HitGen extend collaboration agreement on dyslipidemia project
    Chengdu, China December 23, 2021 Lipigon Pharmaceuticals AB (”Lipigon”), developer of therapeutics for lipid-related diseases, and HitGen Inc. (”HitGen”) have extended the collaboration agreement on the development of small molecules for the treatment of dyslipidemia and cardiometabolic disease until 7 July 2024.
  • 05 November 2021
    HitGen and Cambridge Molecular announce a strategic partnership, bringing together DNA-Encoded Libraries and Deep Learning
    Chengdu, China, and Cambridge, United Kingdom, 5 November 2021 – HitGen Inc. (688222.SH) and Cambridge Molecular are pleased to announce an exclusive alliance, introducing DeepDELve 2 – Cambridge Molecular’s highly optimised DEL-specific deep learning system – as an addition to HitGen’s world-leading DEL discovery platform, with over 1 trillion drug-like small molecules.
  • 01 November 2021
    Vernalis Research - a fully owned subsidiary of HitGen Inc - and Hannibal Innovation announce the creation of Dania Therapeutics ApS
    Chengdu, China, 1 November 2021 – Vernalis Research (“Vernalis”), a fully owned subsidiary of HitGen Inc., and Hannibal Innovation ApS (“Hannibal”) are pleased to announce the creation of Dania Therapeutics ApS (“Dania”) to discover small molecules inhibitors against new undisclosed oncology targets.
  • 29 October 2021
    Infographic|HitGen FY2021 Q3 Report
    Infographic|HitGen FY2021 Q3 Report
  • 02 September 2021
    Veritas In Silico and HitGen Announce Research Collaboration Focused on DNA-Encoded Library Based RNA-targeting small molecule Drug Discovery
    CHENGDU, China, Sep 2nd, 2021-- Shanghai Stock Exchange listed company HitGen Inc. (“HitGen”) and Veritas In Silico Inc. (“Veritas In Silico”), a Tokyo-based private company, today announced that they have entered into a research collaboration agreement to discover small molecule compounds against RNA targets. Veritas In Silico will apply its drug discovery platform, ibVIS, to identify certain RNA targets that are of interest to Veritas In Silico.
  • 31 August 2021
    Infographic | HitGen FY2021 Mid-term Report
    HitGen FY2021 Mid-term Report
  • 10 June 2021
    Vernalis, a fully owned subsidiary of HitGen Inc., and Servier achieve two milestones in their oncology drug discovery collaboration
    Chengdu, China, 10 June 2021 – Vernalis, a fully owned subsidiary of HitGen Inc., and Servier are pleased to announce the achievement of one research and one pre-clinical milestone in their oncology drug discovery collaboration, triggering undisclosed milestone payments to Vernalis.
  • 27 May 2021
    Available now! Whitepaper: Advancing Drug Discovery through DNA Encoded Library Technology!
    CHENGDU, China, May 27th, 2021 HitGen and Fierce Biotech jointly release the Whitepaper: Advancing Drug Discovery through DNA-Encoded Library (DEL) Technology today. This whitepaper will provide the drug discovery community with an in depth dive of DEL technology and stimulate innovation in the field by describing HitGen’s experiences and knowledges on DEL design, synthesis, screening and expanded applications.
  • 24 May 2021
    Dorian and HitGen Announce Research Collaboration Focused on DNA-Encoded Library Based Drug Discovery
    CHENGDU, China, May 24th, 2021-- Shanghai Stock Exchange listed company HitGen Inc. (“HitGen”) today announced that it has entered into a research collaboration agreement with Dorian Therapeutics, Inc.
  • 13 May 2021
    Coming Soon! Whitepaper: Advancing Drug Discovery through DNA-Encoded Library Technology!
    Since its concept was conceived in 1992, DNA-encoded chemical libraries (DELs) have evolved into a valuable technology for hit identification in drug discovery.

Questions?

For more details on how we can advance your innovative drug discovery projects
By submitting your information, you acknowledge having received, read and understood our Privacy Notice as made available above.

We use cookies to provide a better web experience.
By using our site, you acknowledge our use of cookies and please read our Cookie Notice for More information